Last reviewed · How we verify
NCT03281161: SSW2
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
NA trial testing Sun Safe Workplaces Program in Skin Cancer in 1,990 participants. Completed in 31 July 2017.
30 April 2017
Quick facts
| Lead sponsor | Klein Buendel, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 1,990 |
| Start date | 27 February 2015 |
| Primary completion | 30 April 2017 |
| Estimated completion | 31 July 2017 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Sun Safe Workplaces Program
- Attention Control
Conditions studied
- Skin Cancer — all drugs for Skin Cancer →
Sponsor
Klein Buendel, Inc. — full company profile →
Who can join
18 and older, any sex, with Skin Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sun Safe Workplaces (SSW), a comprehensive occupational sun safety program, promoted education and policy to 98 cities, counties, and special districts in Colorado. In a two-year follow-up study, Klein Buendel, Inc. (KB) proposes to examine the effectiveness of SSW on employee sun protection practices by employers and return on investment in an economic evaluation of the cost of the SSW intervention. The results of this follow-up study will provide critical information on effective approaches to increasing sun protection across a wide range of employment sectors with outdoor workers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03281161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sun Safe Workplaces Program
Trials testing the same drug.
- NCT02824289 — Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers · NA · completed
Other recruiting trials for Skin Cancer
Currently open trials in the same condition.
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
- NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
- NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting
Other Klein Buendel, Inc. trials
Trials by the same sponsor.
- NCT07417930 — Hybrid Delivery to Increase Access and Sustainability: Evaluating ezParent Implementation · NA · not yet recruiting
- NCT06894277 — Internet-based Talking About Risk and Adolescent Choices: Health and Emotion Regulation Options · NA · recruiting
- NCT05621044 — Physical Activity Smartphone App for African American Men (FitBros) Ph II · NA · completed
- NCT05618158 — Cancer Prevention for Young Rural Adults · NA · completed
- NCT06235632 — Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03281161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Klein Buendel, Inc.
- Last refreshed: 26 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03281161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing